AHRQ poses questions on sleep apnea
This article was originally published in The Gray Sheet
Agency for Healthcare Research and Quality circulates six questions Oct. 7 on the comparative effectiveness of diagnosis and treatment of obstructive sleep apnea. AHRQ seeks public comments on: how the various available tests compare for diagnosing sleep apnea in adults with symptoms suggestive of disordered sleep; how phased testing compares with full testing alone; what the effect of pre-operative screening for sleep apnea is on surgical outcomes; the comparative effects of various sleep apnea treatments; the pre-treatment patient-level characteristics associated with failure to treat obstructive sleep apnea; and the effect of interventions to improve compliance with sleep apnea treatment devices on clinical outcomes
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.